Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD

By afschroeder • October 24, 2026

Goldman JW, Riess JW, Cho BC, Goldberg SB, Le X, Piotrowska Z, Okamoto I, Yu HA, García-Campelo R, de Castro Carpeño J, Ekman S, Reguart N, Paats MS, Kim SW, Kim YJ, Nishio M, Marrone KA, Smeland KB, Hendriks LEL, Akamatsu H, Shimizu J, Smith PE, Tang KH, Lehman JM, de Langen AJ. Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD. Clin Lung Cancer. 2026 Sep 5;27(9):52-61. doi: 10.1016/j.cllc.2026.09.001. Epub ahead of print. PMID: 42913244.

Tags: combination therapy, Epidermal growth factor receptor, Hematology/Oncology, Non-small cell lung cancer, Pemetrexed, Publications, Tyrosine kinase inhibitor

Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study

Rini BI, Choueiri TK, Voss MH, Burotto M, Oldenburg J, Gurney HP, Ferguson TR, Hammers H, Albiges L, Ürün Y, Romero Diaz RI, Özgüroğlu M,[...]

Systemic Mastocytosis With Associated Acute Myeloid Leukemia Identified After Induction Therapy: A Case Report and Literature Review

Han J, Ghamsari F, Yan J, Kim P. Systemic Mastocytosis With Associated Acute Myeloid Leukemia Identified After Induction Therapy: A Case Report and Literature Review.[...]

Asia-Pacific Transplant Oncology Symposium 2024: Expert Statements on the Current State and Future Direction of Hepatobiliary Surgical and Transplant Oncology

Law JH, Xie K, Yang J, Kudo M, Muthiah MD, Mehta N, Bhoori S, Pinato DJ, Chee CE, Hatano E, Line PD, Chan SL, Doyle[...]